960 related articles for article (PubMed ID: 20547248)
21. Celiac disease: from pathogenesis to novel therapies.
Schuppan D; Junker Y; Barisani D
Gastroenterology; 2009 Dec; 137(6):1912-33. PubMed ID: 19766641
[TBL] [Abstract][Full Text] [Related]
22. Small-bowel mucosal transglutaminase 2-specific IgA deposits in coeliac disease without villous atrophy: a prospective and randomized clinical study.
Kaukinen K; Peräaho M; Collin P; Partanen J; Woolley N; Kaartinen T; Nuutinen T; Halttunen T; Mäki M; Korponay-Szabo I
Scand J Gastroenterol; 2005 May; 40(5):564-72. PubMed ID: 16036509
[TBL] [Abstract][Full Text] [Related]
23. Are transglutaminase 2 inhibitors able to reduce gliadin-induced toxicity related to celiac disease? A proof-of-concept study.
Rauhavirta T; Oittinen M; Kivistö R; Männistö PT; Garcia-Horsman JA; Wang Z; Griffin M; Mäki M; Kaukinen K; Lindfors K
J Clin Immunol; 2013 Jan; 33(1):134-42. PubMed ID: 22878839
[TBL] [Abstract][Full Text] [Related]
24. Oats do not induce systemic or mucosal autoantibody response in children with coeliac disease.
Koskinen O; Villanen M; Korponay-Szabo I; Lindfors K; Mäki M; Kaukinen K
J Pediatr Gastroenterol Nutr; 2009 May; 48(5):559-65. PubMed ID: 19412007
[TBL] [Abstract][Full Text] [Related]
25. Anti-type 2 transglutaminase antibodies as modulators of type 2 transglutaminase functions: a possible pathological role in celiac disease.
Martucciello S; Paolella G; Esposito C; Lepretti M; Caputo I
Cell Mol Life Sci; 2018 Nov; 75(22):4107-4124. PubMed ID: 30136165
[TBL] [Abstract][Full Text] [Related]
26. Altered small-bowel mucosal vascular network in untreated coeliac disease.
Myrsky E; Syrjänen M; Korponay-Szabo IR; Mäki M; Kaukinen K; Lindfors K
Scand J Gastroenterol; 2009; 44(2):162-7. PubMed ID: 18985542
[TBL] [Abstract][Full Text] [Related]
27. Cryptic genetic gluten intolerance revealed by intestinal antitransglutaminase antibodies and response to gluten-free diet.
Not T; Ziberna F; Vatta S; Quaglia S; Martelossi S; Villanacci V; Marzari R; Florian F; Vecchiet M; Sulic AM; Ferrara F; Bradbury A; Sblattero D; Ventura A
Gut; 2011 Nov; 60(11):1487-93. PubMed ID: 21471568
[TBL] [Abstract][Full Text] [Related]
28. A quantitative analysis of transglutaminase 2-mediated deamidation of gluten peptides: implications for the T-cell response in celiac disease.
Dørum S; Qiao SW; Sollid LM; Fleckenstein B
J Proteome Res; 2009 Apr; 8(4):1748-55. PubMed ID: 19239248
[TBL] [Abstract][Full Text] [Related]
29. Specific celiac disease antibodies in children on a gluten-free diet.
Hogen Esch CE; Wolters VM; Gerritsen SA; Putter H; von Blomberg BM; van Hoogstraten IM; Houwen RH; van der Lely N; Mearin ML
Pediatrics; 2011 Sep; 128(3):547-52. PubMed ID: 21859913
[TBL] [Abstract][Full Text] [Related]
30. Celiac disease and autoimmunity.
Troncone R; Discepolo V
J Pediatr Gastroenterol Nutr; 2014 Jul; 59 Suppl 1():S9-S11. PubMed ID: 24979198
[TBL] [Abstract][Full Text] [Related]
31. Transglutaminase, gluten and celiac disease: food for thought. Transglutaminase is identified as the autoantigen of celiac disease.
Marsh MN
Nat Med; 1997 Jul; 3(7):725-6. PubMed ID: 9212095
[No Abstract] [Full Text] [Related]
32. Enhanced B-Cell Receptor Recognition of the Autoantigen Transglutaminase 2 by Efficient Catalytic Self-Multimerization.
Stamnaes J; Iversen R; du Pré MF; Chen X; Sollid LM
PLoS One; 2015; 10(8):e0134922. PubMed ID: 26244572
[TBL] [Abstract][Full Text] [Related]
33. [Intolerance of gluten--a new disease or undiagnosed celiac disease].
Sabel'nikova EA
Eksp Klin Gastroenterol; 2012; (3):87-9. PubMed ID: 22830230
[TBL] [Abstract][Full Text] [Related]
34. Gluten-dependent intestinal autoimmune response.
Korponay-Szabó IR; Simon-Vecsei Z; De Leo L; Not T
Curr Pharm Des; 2012; 18(35):5753-8. PubMed ID: 22726113
[TBL] [Abstract][Full Text] [Related]
35. Interplay between Type 2 Transglutaminase (TG2), Gliadin Peptide 31-43 and Anti-TG2 Antibodies in Celiac Disease.
Martucciello S; Sposito S; Esposito C; Paolella G; Caputo I
Int J Mol Sci; 2020 May; 21(10):. PubMed ID: 32456177
[TBL] [Abstract][Full Text] [Related]
36. Antibodies against deamidated gliadin peptides in early-stage celiac disease.
Kurppa K; Lindfors K; Collin P; Saavalainen P; Partanen J; Haimila K; Huhtala H; Laurila K; Mäki M; Kaukinen K
J Clin Gastroenterol; 2011 Sep; 45(8):673-8. PubMed ID: 21063208
[TBL] [Abstract][Full Text] [Related]
37. T-cell and B-cell immunity in celiac disease.
du Pré MF; Sollid LM
Best Pract Res Clin Gastroenterol; 2015 Jun; 29(3):413-23. PubMed ID: 26060106
[TBL] [Abstract][Full Text] [Related]
38. Celiac sprue.
Cárdenas A; Kelly CP
Semin Gastrointest Dis; 2002 Oct; 13(4):232-44. PubMed ID: 12462708
[TBL] [Abstract][Full Text] [Related]
39. [Recent aspects of antibody determination for the diagnosis of coeliac disease].
Mothes T; Uhlig HH; Richter T
Dtsch Med Wochenschr; 2009 Jul; 134(30):1525-8. PubMed ID: 19603369
[TBL] [Abstract][Full Text] [Related]
40. Tissue transglutaminase antibodies in celiac disease, comparison of an enzyme linked immunosorbent assay and a dot blot assay.
Mankaï A; Sakly W; Landolsi H; Gueddah L; Sriha B; Ayadi A; Sfar MT; Skandrani K; Harbi A; Essoussi AS; Korbi S; Fabien N; Jeddi M; Ghedira I
Pathol Biol (Paris); 2005 May; 53(4):204-9. PubMed ID: 15850953
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
